Celgene
Corporate Headquarters
86 Morris Avenue
Summit
New Jersey
07901
United States
Tel: 908-673-9000
Fax: 908-673-9001
Website: http://www.celgene.com/
About Celgene
At Celgene Corporation, we’re committed to changing the course of human health through bold pursuits in science, life-enhancing therapies and a promise to always put patients first. As a global leader in biotechnology and CAR T cell therapy, Celgene is a place where employees can make a real impact on the lives of patients with unmet medical needs in cancer and inflammatory diseases.
As we rapidly advance our next wave of innovative medicines, we announce the creation of a new global Clinical Development Organization to accelerate and optimize clinical development across our entire mid- to late-stage portfolio. Our commitments in this area will further establish the function as a center of excellence and enhance our strategic leadership in discovery, development and commercialization.
Recognized by Forbes in 2018 as a Top 10 World’s Best Employer and by Business Insider as the #3 Most Reputable Pharma Company in the World, Celgene offers a unique work environment where you can help build the business, while building your career in ways you may not have thought possible. We’re looking for innovative self-starters who want to improve the lives of patients worldwide. For more information, visit https://www.celgene.com/careers/.
CAR T cell therapy is a groundbreaking immunotherapy treatment that leverages a patient’s own immune system in fighting their cancer. Celgene is looking for dedicated people to join our team in this exciting area of cancer treatment.
1081 articles with Celgene
-
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
5/24/2019
Bristol-Myers Squibb Company announced the extension of the expiration date of the offers to exchange notes issued by Celgene Corporation for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company and cash and the related consent solicitations being made by Bristol-Myers Squibb on behalf of Celgene to adopt certain proposed amendments to the indentures governing the Celgene Notes.
-
Celgene and the Multiple Sclerosis Association of America Team Up to Launch MS MindShift for Awareness of Multiple Sclerosis and Brain Health
5/21/2019
“Brain Bulb” Hot Air Balloon Takes Flight in NYC Area to Elevate Importance of Brain Preservation
-
Celgene to Highlight New and Updated Hematology and Oncology Clinical Data at Upcoming American Society of Clinical Oncology (ASCO) 2019 Annual Meeting
5/15/2019
Presentations include innovative cancer research, including novel CAR T technology, as well as key disease areas, including myelofibrosis and multiple myeloma
-
Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma
5/13/2019
Celgene Corporation announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to POMALYST® (pomalidomide) for the treatment of patients with human immunodeficiency virus (HIV)-positive Kaposi sarcoma who have previously received systemic chemotherapy, as well as patients with HIV‐negative Kaposi’s sarcoma.
-
Lyfebulb and Celgene Announce Finalists for 2019 "Addressing Unmet Needs in MS: An Innovation Challenge"
5/10/2019
Finalist patient entrepreneurs recognized for potential of innovations in multiple sclerosis (MS)
-
Analysis Showed Oral Ozanimod Reduced Brain Volume Loss Across All Age Subgroups in Adults with Relapsing Multiple Sclerosis
5/7/2019
Data from new analysis of pivotal ozanimod trial will be presented at 2019 AAN Annual Meeting
-
Bristol-Myers Squibb Company Announces Results of Early Participation in Exchange Offers and Consent Solicitations for Celgene Corporation Notes
5/2/2019
Bristol-Myers Squibb Company announced that the requisite number of consents have been received to adopt proposed amendments with respect to all outstanding notes of Celgene Corporation.
-
Presage Announces Collaboration with Celgene to Investigate Novel Agents with CIVO™ Technology
5/2/2019
Research agreement to support Phase 0 tumor microdosing studies
-
Celgene Corporation and bluebird bio published interim data from CRB-401, their Phase I trial of bb2121, their CAR-T therapy in patients with relapsed and refractory multiple myeloma.
-
Celgene Corporation and bluebird bio Announce Results from Ongoing Multicenter Phase 1 Study of bb2121 anti-BCMA CAR T Cell Therapy in Patients with Multiple Myeloma Published in New England Journal of Medicine
5/1/2019
The manuscript, “Anti-BCMA CAR T Cell Therapy bb2121 in Relapsed/Refractory Multiple Myeloma”, published in NEJM includes key safety and efficacy results from the dose escalation and first expansion cohort, including a minimum of six months follow up on all subjects.
-
Whenever drug companies come under criticism for the cost of their drugs, one of the defenses touted is that only about one in 10 drugs make it to market. As a broad figure, that’s probably about right, although at least one report ranks it higher, while another provides a bit more nuance.
-
Celgene, which will become part of Bristol-Myers Squibb later this year, saw positive growth in the first quarter of the year.
-
Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Marketing Authorization Application to the European Medicines Agency (EMA) for MDS and Beta-Thalassemia
4/26/2019
Submission to EMA follows Biologics Licensing Application submission to U.S. FDA earlier this month
-
Arrakis Therapeutics Announces $75 Million Series B Financing to Advance a New Class of Small-Molecule Medicines Targeting RNA
4/18/2019
Having established first-in-industry RNA-targeted Small Molecule (rSM) platform, Arrakis will focus pipeline in oncology and genetically validated targets in other diseases
-
Although it was probably not in serious jeopardy, Bristol-Myers Squibb’s shareholders voted today to approve the acquisition of Celgene Corporation for about $74 billion.
-
Celgene and its developmental partner Acceleron Pharma are eying a potential U.S. Food and Drug Administration approval of a blood-disease treatment.
-
Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Biologics License Application to U.S. FDA
4/5/2019
BLA submission includes both myelodysplastic syndromes and beta-thalassemia indications
-
Starboard Value Backs Down From BMS/Celgene Fight After Proxy Advisory Firms Announce Support
4/1/2019
Shares of Bristol-Myers Squibb are up slightly this morning after the proposed $74 billion acquisition of Celgene gained some significant support over the weekend. That support has caused at least one opposition group to withdraw from the fight. -
Celgene Receives CHMP Positive Opinions for Both REVLIMID® (lenalidomide) and IMNOVID® (pomalidomide)-Based Triplet Combination Regimens for Patients with Multiple Myeloma
3/29/2019
REVLIMID in combination with bortezomib and dexamethasone (RVd) in adult patients with previously untreated multiple myeloma who are not eligible for transplant
-
Supporters and those opposed to the proposal are marshaling their forces ahead of the April 12 shareholder vote.